Skip to main content

APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes

NCT03233204

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes

Associated Conditions

Cancer, All Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

The main goal is to test any good and bad effects of the study drug olaparib on your tumor. A second goal of the study is to evaluate side effects that might be caused by olaparib and to learn more about the pharmacology (how your body handles the study drug) olaparib.